A veteran digital and television journalist, Michelle Fox writes articles for CNBC.com and acts as a liaison between the website and CNBC television shows.
Prior to joining CNBC.com, she spent years on the broadcast side of the business, including an earlier stint at CNBC. Fox has also worked at MSNBC, Court TV and WCBS-TV in New York, where she earned an Emmy award for anticipated breaking news coverage.
Apple and other multinational companies can expect to start paying a lot more taxes in the coming years, law professor Edward Kleinbard says.
Redfin's chief economist, Nela Richardson, says the housing market is contracting, not expanding into a bubble.
Extremely valued dividend stocks will underperform, it's just a matter of timing, Vadim Zlotnikov says.
A changing landscape and studio problems may be hurting the summer box office, but there is good news, BoxOffice.com's Daniel Loria says.
Things like Mylan's EpiPen price hikes will keep happening unless these changes are made, former Vermont Gov. Howard Dean says.
Shares of St. Jude Medical could drop to $55 or lower if the Abbott Laboratories' deal falls apart, Muddy Waters' Carson Block said.
If Mylan's CEO wants to lower the price of the EpiPen today, she could, Express Scripts' Dr. Steve Miller says.
There needs to be more transparency in drug pricing, and Mylan still has a lot of questions to answer, Sen. Charles Grassley said Thursday.
The market is trading in a narrow range, but there is opportunity to make higher returns if investors know where to look, two experts say.